Increasing Vaccine Uptake in Underresourced Public Housing Areas

Coronavirus Clinical Trial

Official title:

Community Partnered Intervention to Increase COVID-19 Vaccine Uptake in Low Income Underresourced African Americans and Latinx Public Housing Residents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04779138
• Other study ID #: vaccinehousing
• Status: Completed
• Phase: N/A
• Start date: September 11, 2021
• Est. completion date: April 1, 2024

Study information

• Verified date: February 2024
• Source: Charles Drew University of Medicine and Science
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This proposal seeks to enhance uptake and completion of COVID-19 vaccination among African American and Latinx public housing residents in South Los Angeles. Given the multiple disparities experienced by public housing residents, the investigators will utilize a theoretically-based, multidisciplinary and culturally tailored intervention to provide education at multiple levels and implement innovate strategies to engage this population in the uptake of COVID-19 vaccination.

Description:

One particular group, African American and Latinx public housing residents, are facing adverse effects related to worsening social determinants and health disparities. Utilizing a community-driven approach, the overall objective of this proposed study is to increase COVID-19 vaccine uptake and completion the impact of COVID-19 among African American and Latinx public housing residents. Guided by the Community Based Participatory Model, the Information, Motivation, and Behavioral Skills (IMB) and the Transtheoretical Model will be utilized to carry out this intervention. Through this innovative program, we will establish Academic-Community Team for Improving Vaccine Acceptability and Targeted Engagement (ACTIVATE) program, which will develop leadership triads of public housing resident leaders, nurse practitioner students, and public health students to carry out this multilevel intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 462
• Est. completion date: April 1, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Aim 2:

Inclusion Criteria:

• identify as Latinx or African American
• age 18 or older
• reside in one of the six collaborating public housing area
• Speak either English or Spanish

Exclusion Criteria:

• Not a resident at one of the collaborating public housing areas
• Does not self-identify as African American or Latinx
• Age 17 and younger
• Unable to speak either English or Spanish Aim 3:

Inclusion Criteria:

• identify as Latinx or African American
• age 18 or older
• reside in one of the six collaborating public housing area
• Speak either English or Spanish
• Report vaccine hesitancy

Exclusion Criteria:

• Not a resident at one of the collaborating public housing areas
• Does not self-identify as African American or Latinx
• Age 17 and younger
• Unable to speak either English or Spanish
• Received all recommended vaccines for COVID-19
• No reporting of vaccine hesitancy

Related Conditions & MeSH terms

• Coronavirus
• Coronavirus Infections
• Vaccine Refusal

Intervention

Behavioral:
• Increasing Willingness and Uptake of COVID-19 Vaccination
Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.

Locations

Country	Name	City	State
United States	Charles R. Drew University of Medicine & Science	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Charles Drew University of Medicine and Science

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report	1. By comparison of pre-, post- intervention, and 9- and 18-months follow-up data, we anticipate the following compared to baseline: a 40% change in completion of COVID-19 vaccination series	Intervention: 4 months; Follow-up Point: 3 months post-intervention
Secondary	Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19 vaccine Using the NIH Toolbox Surveys on COVID-19	1. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in hesitancy toward COVID-19 vaccination.	Intervention: 4 months; Follow-up Point: 3 months post-intervention
Secondary	Percentage of Participants Achieving Increased Level of Behavior Change toward COVID-19 Vaccination Using the NIH Toolbox Surveys on COVID-19	2. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in their behavior stage of change toward COVID-19 vaccination	Intervention: 4 months; Follow-up Point: 3 months post-intervention